France Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

France Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

France Professional Acne Medication Market was valued at USD 57.08 million in 2023 and is predicted to reach USD 119.62 million by 2030, with a CAGR of 11.15% from 2024 to 2030. The professional acne medication market refers to specialized skincare formulations prescribed by dermatologists for targeted and effective acne treatment, addressing both inflammatory and non-inflammatory lesions while preventing scarring. These formulations offer advantages such as potent and tailored ingredients, often surpassing over-the-counter options.

Widely utilized in dermatology practices, professional acne medications cater to individuals with severe or persistent acne concerns, ensuring a higher level of efficacy and control. As the demand for advanced skincare rises, this market remains pivotal, providing personalized and medically guided approaches for achieving clearer and healthier skin.

Beauty-Driven Culture Fuels the Market

The driving force behind the growth of the professional acne medication market in France lies in the country's deep-rooted culture of beauty and skincare. The longstanding tradition of valuing clear, healthy skin, translates into a consistent demand for professional acne treatments. The population places a significant premium on personal appearance and actively seeks professional dermatological care to achieve and sustain clear, blemish-free skin. The region’s beauty-conscious culture catalyses innovative dermatological solutions and the increasing popularity of these services among individuals striving to attain and maintain radiant, blemish-free skin.

 

Presence of Advanced Healthcare Infrastructure Drives the Market

France's professional acne medication market benefits significantly from its advanced healthcare infrastructure. The country's well-equipped medical facilities and highly skilled healthcare workforce offer several advantages for the growth of the market. Patients can confidently seek top-notch care, including advanced dermatological treatments, knowing they will receive effective and reliable solutions for their skin concerns. As a result, the market experiences steady growth due to the excellent healthcare infrastructure that supports the accessibility and quality of professional acne care.

 

Regulatory Challenges Restrains the Market

The growth of the professional acne medication market faces significant hindrances due to regulatory hurdles in the healthcare sector. The French healthcare system is known for its strict regulations and stringent compliance standards, which have the unintended consequence of posing substantial barriers to the entry and expansion of the professional acne medication market. Navigating this complex regulatory landscape is particularly challenging for both domestic and foreign market players, effectively slowing down the growth trajectory of the industry.

Emphasis on Telemedicine and Online Consultations are Creating Opportunities for  Market Growth

Telemedicine and online consultations have emerged as promising avenues for future opportunities in the growth of the professional acne medication market in France. This advancement is driven by the increasing popularity of telehealth services, which enable patients to consult with dermatologists and other healthcare professionals remotely. These virtual consultations are highly convenient, especially for those residing in underserved areas with limited access to dermatological care.

Patients can discuss their acne-related concerns, receive personalized treatment recommendations, and even obtain prescriptions through these virtual appointments. This improves access to professional acne care and aligns with the growing trend of convenient, patient-centric healthcare services, ultimately contributing to the future growth of the professional acne medication market.

 

Competitive Landscape

The France professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

France Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 57.08 Million

Revenue Forecast in 2030

USD 119.62 Million

Growth Rate

CAGR of 11.1% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Increasing skincare awareness

Advanced healthcare infrastructure.

Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      FRANCE PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       FRANCE PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       FRANCE PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       FRANCE PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       FRANCE PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 19. ALMIRALL S.A.: OPERATING BUSINESS SEGMENTS

TABLE 20. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 21. ALMIRALL S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. ALMIRALL S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. ALMIRALL S.A.: KEY STRATERGY

TABLE 24. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 25. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 26. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 27. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 30. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 31. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 32. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 33. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 36. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 37. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 38. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 39. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. GALDERMA S.A.: KEY STRATERGY

TABLE 42. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 43. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 54. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 56. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 57. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 60. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 61. ELI LILLY AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 62. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 63. ELI LILLY AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. ELI LILLY AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. ELI LILLY AND COMPANY: KEY STRATERGY

TABLE 66. MYLAN N.V.: COMPANY SNAPSHOT

TABLE 67. MYLAN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 68. MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 69. MYLAN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. MYLAN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. MYLAN N.V.: KEY STRATERGY

TABLE 72. DAIICHI SANKYO COMPANY, LTD: COMPANY SNAPSHOT

TABLE 73. DAIICHI SANKYO COMPANY, LTD: OPERATING BUSINESS SEGMENTS

TABLE 74. DAIICHI SANKYO COMPANY, LTD: PRODUCT PORTFOLIO

TABLE 75. DAIICHI SANKYO COMPANY, LTD: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. DAIICHI SANKYO COMPANY, LTD: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. DAIICHI SANKYO COMPANY, LTD: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. FRANCE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. ALMIRALL S.A.: NET SALES, (2021-2023)

FIGURE 24. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 25. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 26. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 27. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 28. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 29. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 30. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 31. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 32. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 34. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 35. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 36. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 37. ELI LILLY AND COMPANY: NET SALES, (2021-2023)

FIGURE 38. ELI LILLY AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 39. MYLAN N.V.: NET SALES, (2021-2023)

FIGURE 40. MYLAN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 41. DAIICHI SANKYO COMPANY, LTD: NET SALES, (2021-2023)

FIGURE 42. DAIICHI SANKYO COMPANY, LTD: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the France professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the France professional acne medication market business is expected to hit at USD 119.62 million by 2030.

What are the leading companies in the France professional acne medication market?

The France professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

What are the market segmentations and scope of the study for the France professional acne medication industry?

The France professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in France?

The growth of the professional acne medication market in France is primarily driven by elevated skincare awareness and advanced healthcare infrastructure.

What is restraining the growth of the France professional acne medication market?

The high healthcare costs and limited insurance coverage present a substantial restraint on the market's growth in France.